Diagnosis of antiphospholipid syndrome

References

• Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum.42(7), 1309–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4(2), 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes GR. Hughes syndrome (the antiphospholipid syndrome): ten clinical lessons. Autoimmun. Rev.7(3), 262–266 (2008).
   PubMed Web of Science ®Google Scholar
• Asherson RA, Khamashta MA, Ordi-Ros J et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore)68(6), 366–374 (1989).
   PubMed Web of Science ®Google Scholar
• Vianna JL, Khamashta MA, Ordi-Ros J et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am. J. Med.96(1), 3–9 (1994).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med.100(5), 530–536 (1996).
   PubMed Web of Science ®Google Scholar
• Krnic-Barrie S, O’Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch. Intern. Med.157(18), 2101–2108 (1997).
   PubMedGoogle Scholar
• Piette JC, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation97(22), 2195–2196 (1998).
   PubMed Web of Science ®Google Scholar
• Godfrey T, D’Cruz D. Antiphospholipid syndrome: general features. In: Hughes syndrome Antiphospholipid syndrome. Khamashta MA (Ed.). Springer-Verlag, London, UK, 8–19 (2000).
   Google Scholar
• Molina JF, Gutierrez-Urena S, Molina J et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J. Rheumatol.24(2), 291–296 (1997).
   PubMed Web of Science ®Google Scholar
• Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin and anti-β2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am. J. Med. Sci.318(1), 55–60 (1999).
   PubMed Web of Science ®Google Scholar
• Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum.46(4), 1019–1027 (2002).
   PubMed Web of Science ®Google Scholar
• Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus7(1), 3–6 (1998).
   PubMed Web of Science ®Google Scholar
• Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke28, 2363–2369 (1997).
   PubMed Web of Science ®Google Scholar
• Deschiens MA, Conard J, Horellou MH et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke27, 1724–1730 (1996).
   PubMed Web of Science ®Google Scholar
• Ijdo JW, Conti-Kelly AM, Greco P et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus8, 109–115 (1999).
   PubMed Web of Science ®Google Scholar
• Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GRV. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore)79(1), 57–68 (2000).
   PubMed Web of Science ®Google Scholar
• Nochy D, Daugas E, Droz D et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J. Am. Soc. Nephrol.10(3), 507–518 (1999).
   PubMed Web of Science ®Google Scholar
• Sangle SR, D’Cruz DP, Jan W et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann. Rheum. Dis.62(10), 999–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N. Engl. J. Med.313(21), 1322–1326 (1985).
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Druzin ML, Goei S et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N. Engl. J. Med.313(3), 152–156 (1985).
   PubMed Web of Science ®Google Scholar
• Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol.80(4), 614–620 (1992).
   PubMed Web of Science ®Google Scholar
• Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L, Mancuso S. Pregnancy outcome in relation to uterine artery flow velocity waveforms and clinical characteristics in women with antiphospholipid syndrome. Obstet. Gynecol.82(6), 970–977 (1993).
   PubMed Web of Science ®Google Scholar
• Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin. Exp. Rheumatol.14(2), 131–136 (1996).
   PubMed Web of Science ®Google Scholar
• Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ330(7491), 565 (2005).
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum.43, 440–443 (2000).
   PubMed Web of Science ®Google Scholar
• Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GRV. Specificity of ELISA for antibody to β2-glycoprotein I in patients with antiphospholipid syndrome. Br. J. Rheumatol.35(12), 1239–1243 (1996).
   PubMedGoogle Scholar
• Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β 2-glycoprotein-I than with antiphospholipid antibodies. J. Rheumatol.22(10), 1899–1906 (1995).
   PubMed Web of Science ®Google Scholar
• Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to β 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum.39(9), 1606–1607 (1996).
   PubMedGoogle Scholar
• Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndrome: a primary variant with antibodies to β2 glycoprotein I but no antibodies detectable in standard antiphospholipid assay. Am. J. Med.101, 472–481 (1996).
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR. The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to β 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J. Rheumatol.24(8), 1545–1551 (1997).
   PubMed Web of Science ®Google Scholar
• Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med.117, 997–1002 (1992).
   PubMed Web of Science ®Google Scholar
• Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med.104, 332–338 (1998).
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med.179(2), 457–462 (1994).
   PubMed Web of Science ®Google Scholar
• Galli M, Borrelli G, Jacobsen EM et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood110(4), 1178–1183 (2007).
   PubMed Web of Science ®Google Scholar
• Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N. Engl. J. Med.346(10), 752–763 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes GR. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad. Med. J.79(928), 81–83 (2003).
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Atsumi T, Escudero-Contreras A, Khamashta MA, Hughes GRV. The value of IgA antiphospholipid testing for the diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J. Rheumatol.28(12), 2637–2643 (2001).
   PubMed Web of Science ®Google Scholar
• Diri E, Cucurull E, Gharavi AE et al. Antiphospholipid (Hughes’) syndrome in African-Americans: IgA aCL and aβ2 glycoprotein-I is the most frequent isotype. Lupus8(4), 263–268 (1999).
   PubMed Web of Science ®Google Scholar
• Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost.74, 1185–1190 (1995).
   PubMed Web of Science ®Google Scholar
• Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br. J. Haematol.109(4), 704–715 (2000).
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Derksen RH, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome. Blood Rev.22, 93–105 (2008).
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb. Haemost.68, 297–300 (1992).
   PubMed Web of Science ®Google Scholar
• Viard JP, Amoura Z, Bach JF. Association of anti-β 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am. J. Med.93(2), 181–186 (1992).
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood101(5), 1827–1832 (2003).
   PubMed Web of Science ®Google Scholar
• Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J. Rheumatol.33(11), 2214–2221 (2006).
   PubMed Web of Science ®Google Scholar
• Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus – a meta-analysis. Lupus6(5), 467–473 (1997).
   PubMed Web of Science ®Google Scholar
• Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus7(1), 15–22 (1998).
   PubMed Web of Science ®Google Scholar
• Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between β2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J. Thromb. Haemost.1(4), 740–747 (2003).
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antiβ-glycoprotein I lupus anticoagulants. J. Thromb. Haemost.2(5), 702–707 (2004).
   PubMed Web of Science ®Google Scholar
• de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood104(12), 3598–3602 (2004).
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, Barbui T. Anti-β 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood102(8), 2717–2723 (2003).
   PubMed Web of Science ®Google Scholar
• Asherson RA, Cervera R, de Groot PG et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus12(7), 530–534 (2003).
   PubMed Web of Science ®Google Scholar
• Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann. Rheum. Dis.62(12), 1127 (2003).
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Roch B, Amengual O, Atsumi T, Khamashta MA, Hughes GRV. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br. J. Rheumatol.37(11), 1229–1232 (1998).
   PubMedGoogle Scholar
• Bertolaccini ML, Gomez S, Pareja JF et al. Antiphospholipid antibody tests: spreading the net. Ann. Rheum. Dis.64(11), 1639–1643 (2005).
   PubMed Web of Science ®Google Scholar